Overview

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the dose response following single inhalation of Ba 679 BR inhalation powder in COPD patients using pulmonary functions as indicators, and to compare data obtained with overseas study findings
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Tiotropium Bromide